Clinical Trials
Diabetic Retinopathy
Active Studies
ALTITUDE (RegenxBio)
A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME).
GLOW2 (Kodiak)
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
LTFU NPDR (RegenxBio)
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema.
Completed Studies
CYSTOID MACULAR EDEMA AFTER CATARACT SURGERY (Allergan)
Phase 2 Study Of The Dexamethasone Intravitreal Implant (Ozurdex) For Combined Pseudophakic Cystoid Edema And Diabetic Macular Edema After Cataract Surgery.
DA VINCI (Regeneron)
Phase 2 Study Of The Safety, Tolerability And Biological Effect Of Repeated Aflibercept (Eylea) In Diabetic Macular Edema.
DEGAS (Pfizer)
Phase 2 Study Of The Efficacy And Safety Of PF-04523655 Versus Laser In Diabetic Macular Edema.
PACIFIC (Allegro)
A 6 Month, Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed To Evaluate The Safety And Efficacy Of Luminate In Inducing PVD In Subjects With Non-proliferative Diabetic Retinopathy.
PANORAMA (Regeneron)
A 2 Year, Phase 3, Multicenter, Randomized Study Of The Efficacy And Safety Of Intravitreal Aflibercept (Eylea) Injection In Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy.
RIDE (Genentech)
Phase 3 Study Of The Efficacy And Safety Of Ranibizumab (Lucentis) In Diabetic Macular Edema.
SPECTRA (Valo)
Phase 2 Spectra Study To Evaluate The Safety And Efficacy Of OPL-0401 In Patients With Diabetic Retinopathy
VISTA (Regeneron)
A 3 Year Phase 3 Study Of The Efficacy, Safety And Tolerability Of Aflibercept (Eylea) In Patients With Diabetic Macular Edema.
